Short Interest in Evolus Inc (NASDAQ:EOLS) Increases By 15.1%
Evolus Inc (NASDAQ:EOLS) saw a large growth in short interest in January. As of January 31st, there was short interest totalling 6,560,000 shares, a growth of 15.1% from the January 15th total of 5,700,000 shares. Based on an average trading volume of 638,300 shares, the days-to-cover ratio is presently 10.3 days. Approximately 29.4% of the company’s shares are short sold.
Shares of NASDAQ EOLS traded up $0.35 during trading on Friday, hitting $9.69. The stock had a trading volume of 670,377 shares, compared to its average volume of 738,832. Evolus has a 12 month low of $9.20 and a 12 month high of $29.50. The company has a debt-to-equity ratio of 4.53, a current ratio of 3.66 and a quick ratio of 3.28. The company has a market capitalization of $323.89 million, a PE ratio of -3.02 and a beta of 4.30. The firm has a fifty day moving average of $10.71 and a two-hundred day moving average of $14.03.
EOLS has been the subject of a number of research analyst reports. Leerink Swann started coverage on Evolus in a research report on Tuesday, November 26th. They issued an “outperform” rating and a $25.00 target price for the company. ValuEngine upgraded Evolus from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 23rd. Mizuho started coverage on Evolus in a research note on Wednesday, February 5th. They issued a “buy” rating and a $20.00 price objective for the company. Svb Leerink started coverage on Evolus in a research note on Tuesday, November 26th. They issued an “outperform” rating and a $25.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating on shares of Evolus in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Evolus has a consensus rating of “Buy” and a consensus target price of $25.45.
Several hedge funds have recently made changes to their positions in EOLS. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Evolus by 2,224.0% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,324 shares of the company’s stock worth $34,000 after buying an additional 2,224 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Evolus during the fourth quarter valued at approximately $30,000. Metropolitan Life Insurance Co NY bought a new stake in Evolus during the first quarter worth $83,000. Royal Bank of Canada lifted its holdings in Evolus by 429.1% during the second quarter. Royal Bank of Canada now owns 4,365 shares of the company’s stock worth $64,000 after acquiring an additional 3,540 shares during the period. Finally, FMR LLC lifted its holdings in Evolus by 1,328.6% during the fourth quarter. FMR LLC now owns 5,000 shares of the company’s stock worth $61,000 after acquiring an additional 4,650 shares during the period. Institutional investors own 16.91% of the company’s stock.
Evolus Company Profile
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Recommended Story: Price-Sales Ratio
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.